Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of S-524101 sublingual tablets in pediatric perennial allergic rhinitis
jRCT2080222929Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Aug 2015
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in perennial rhinitis comparing S-524101 300 IR with Placebo (2 arms). Primary endpoint: Symptom improvement of house dust mite-induced allergic rhinitis. Started Aug 2015; status: completed.
02
Drugs
House dust mite allergen extract
03
Conditions
perennial rhinitis
Beyond the preview
Go deeper on jRCT2080222929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222929.